New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy – QNT Press Release


DURHAM, NC, May 22, 2022 /PRNewswire/ — New data shows that more than a third (36.6%) of ulcerative colitis (UC) patients who have previously responded to advanced therapies experienced a loss of remission (LOR) in their symptom control, often within a year. The analysis from Target RWE’s TARGET-IBD large, longitudinal cohort, Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis, [Su1537] was presented today by Benjamin ClickMD, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, at Digestive Disease Week in San Diego.

Recommended For You

About the Author: News Center